JNJ- Johnson & Johnson
Johnson & Johnson (JNJ) has 23 insiders with recent SEC Form 4 filings, including 1 buy and 19 sells. JNJ is classified in the Pharmaceuticals industry within the Health Care sector.
Insider Ownership
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| 10% | 4.04M | $1.04B | - | |
| VP | 114.3K | $29.44M | - | |
| CEO | 79.6K | $20.51M | - | |
| VP | 46.2K | $11.91M | - | |
| VP | 46.1K | $11.86M | -23,054 |
Activity
Buys and sells only
Transactions
10 filings
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jul 20, 2026 | Broadhurst Vanessa | EVP, Global Corp Affairs | Sale+OE | 23,054 | $251.27 | $5,792,686.36 | -50.1% | - | - | |
| Feb 17, 2026 | Reed John C | EVP, Innovative Medicine, R&D | Sale+OE | 53,931 | $243.00 | $13,105,233.00 | -59.6% | -6.8% | - | |
| Feb 17, 2026 | Swanson James D. | EVP, CIO | Sale+OE | 62,080 | $243.39 | $15,109,758.99 | -45.0% | -6.8% | - | |
| Feb 17, 2026 | Wolk Joseph J | Exec VP, CFO | Sale+OE | 89,654 | $242.80 | $21,767,826.99 | -40.7% | -6.8% | - | |
| Jan 26, 2026 | Duato Joaquin | CEO And Chairman Of The Board | Sell | 100,000 | $221.23 | $22,122,893.44 | -47.5% | - | - | |
| Nov 26, 2025 | Johnson & Johnson59 | 10% Owner | Sell | 6,337 | $10.03 | $63,560.11 | -0.2% | +18.7% | - | |
| Nov 26, 2025 | Morikis John G64 | Director | Buy | 1,250 | $206.15 | $257,687.50 | +208.9% | +18.7% | - | |
| Nov 24, 2025 | Johnson & Johnson59 | 10% Owner | Sell | 2,700 | $10.05 | $27,132.00 | - | +19.3% | - | |
| Nov 12, 2025 | Johnson & Johnson59 | 10% Owner | Sell | 1,000 | $10.00 | $10,000.00 | - | +22.6% | - | |
| Nov 7, 2025 | Johnson & Johnson59 | 10% Owner | Sell | 52,532 | $10.21 | $536,309.72 | -0.6% | +27.5% | - |
Page 1Next →